[{"id":"e3084173-3132-4e56-b647-4f08a948793b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01761968","created_at":"2024-03-29T16:38:22.645Z","updated_at":"2024-07-02T16:35:12.297Z","phase":"Phase 2","brief_title":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","source_id_and_acronym":"NCT01761968","lead_sponsor":"Italfarmaco","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Duvyzat (givinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-29"},{"id":"81f945cb-5dfa-4632-b320-22d02b5e3f53","acronym":"","url":"https://clinicaltrials.gov/study/NCT00606307","created_at":"2021-01-18T02:15:01.813Z","updated_at":"2024-07-02T16:36:52.963Z","phase":"Phase 2a","brief_title":"Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases","source_id_and_acronym":"NCT00606307","lead_sponsor":"Italfarmaco","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Duvyzat (givinostat)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 12/01/2007","start_date":" 12/01/2007","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 12/01/2008","study_completion_date":" 12/01/2008","last_update_posted":"2019-12-03"}]